Two laboratories, the American Pfizer and the German BioNTech, have revealed the development of a vaccine that would be 90% effective, according to the result of the first interim analysis of phase 3.
A promising new vaccine
The two laboratories claimed that the vaccine is ” 90% efficient ”, According to the first interim analysis of their phase 3 trial, which is the last step before a license application. Pfizer Chairman and CEO Albert Bourla said: “ More than eight months after the start of the worst pandemic in more than a century, we believe this step represents a significant step forward for the world in our battle against Covid-19 “While also adding that” the first set of results from our phase 3 Covid-19 vaccine trial provides initial evidence of our vaccine’s ability to prevent Covid-19 “. THE’ ” vaccine efficacy “Turned out” seven days after the second dose »And 28 after the premiere. Two groups were compared: one in which participants infected with the new coronavirus received the vaccine and another placed on placebo. Of the 43,000 participants in the phase 3 study cohort, only 94 patients contracted Covid-19. This vaccine would therefore be ” 90% efficient », Reveal the Pfizer and Biontech laboratories. A victory for the two laboratories, which could make this vaccine available to the world population in a few months.
The vaccine, soon to be marketed?
The vaccine could be available before the end of the year for some countries, given priority to members of hospital staff. The two laboratories have indicated that an emergency authorization could be validated before the end of the month, as all criteria are met, including efficacy, absence of health risk and the ability to produce on a large scale. Many companies have already planned to deliver up to 50 million doses of vaccine globally in 2020 and up to 1.3 billion doses in 2021.
